70 related articles for article (PubMed ID: 26206047)
1. [New oral therapy option].
Grzegorek K
MMW Fortschr Med; 2015 Jul; 157(13):77. PubMed ID: 26206047
[No Abstract] [Full Text] [Related]
2. Genotype-based treatment approved for type 1 Gaucher disease.
Thompson CA
Am J Health Syst Pharm; 2014 Oct; 71(19):1606. PubMed ID: 25225441
[No Abstract] [Full Text] [Related]
3. Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy.
Zimran A; Goldblatt J; Szer J
Blood Cells Mol Dis; 2018 Feb; 68():14-16. PubMed ID: 28935503
[No Abstract] [Full Text] [Related]
4. Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Mistry PK; Balwani M; Baris HN; Turkia HB; Burrow TA; Charrow J; Cox GF; Danda S; Dragosky M; Drelichman G; El-Beshlawy A; Fraga C; Freisens S; Gaemers S; Hadjiev E; Kishnani PS; Lukina E; Maison-Blanche P; Martins AM; Pastores G; Petakov M; Peterschmitt MJ; Rosenbaum H; Rosenbloom B; Underhill LH; Cox TM
Blood Cells Mol Dis; 2019 Jul; 77():101-102. PubMed ID: 31029022
[No Abstract] [Full Text] [Related]
5. Overcoming the Next Barriers to Successful Therapy.
Cohen IJ; Baris H; Mistry PK; Sands MS
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209
[No Abstract] [Full Text] [Related]
6. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States.
Balwani M; Burrow TA; Charrow J; Goker-Alpan O; Kaplan P; Kishnani PS; Mistry P; Ruskin J; Weinreb N
Mol Genet Metab; 2016 Feb; 117(2):95-103. PubMed ID: 26387627
[TBL] [Abstract][Full Text] [Related]
7. Type 1 Gaucher disease (CYP2D6-eliglustat).
Becquemont L
Therapie; 2017 Apr; 72(2):323-326. PubMed ID: 28242126
[TBL] [Abstract][Full Text] [Related]
8. Eliglustat: first global approval.
Poole RM
Drugs; 2014 Oct; 74(15):1829-36. PubMed ID: 25239269
[TBL] [Abstract][Full Text] [Related]
9. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
Belmatoug N; Di Rocco M; Fraga C; Giraldo P; Hughes D; Lukina E; Maison-Blanche P; Merkel M; Niederau C; PlÓ§ckinger U; Richter J; Stulnig TM; Vom Dahl S; Cox TM
Eur J Intern Med; 2017 Jan; 37():25-32. PubMed ID: 27522145
[TBL] [Abstract][Full Text] [Related]
10. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Lukina E; Watman N; Dragosky M; Pastores GM; Arreguin EA; Rosenbaum H; Zimran A; Angell J; Ross L; Puga AC; Peterschmitt JM
Blood Cells Mol Dis; 2014 Dec; 53(4):274-6. PubMed ID: 24835462
[TBL] [Abstract][Full Text] [Related]
11. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.
Lukina E; Watman N; Arreguin EA; Dragosky M; Iastrebner M; Rosenbaum H; Phillips M; Pastores GM; Kamath RS; Rosenthal DI; Kaper M; Singh T; Puga AC; Peterschmitt MJ
Blood; 2010 Nov; 116(20):4095-8. PubMed ID: 20713962
[TBL] [Abstract][Full Text] [Related]
12. Eliglustat (Cerdelga)--An Oral Drug for Gaucher Disease.
Med Lett Drugs Ther; 2015 Jul; 57(1472):e100-1. PubMed ID: 26147895
[No Abstract] [Full Text] [Related]
13. A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.
Peterschmitt MJ; Cox GF; Ibrahim J; MacDougall J; Underhill LH; Patel P; Gaemers SJM
Blood Cells Mol Dis; 2018 Feb; 68():185-191. PubMed ID: 28126395
[TBL] [Abstract][Full Text] [Related]
14. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
15. Glucocerebrosidase inhibitors: future drugs for the treatment of Gaucher disease?
Trapero A; Llebaria A
Future Med Chem; 2014 Jun; 6(9):975-8. PubMed ID: 25068980
[No Abstract] [Full Text] [Related]
16. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.
Cox TM
Curr Opin Investig Drugs; 2010 Oct; 11(10):1169-81. PubMed ID: 20872320
[TBL] [Abstract][Full Text] [Related]
17. Imino sugar therapy for type 1 Gaucher disease.
Priestman DA; Platt FM; Dwek RA; Butters TD
Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
[No Abstract] [Full Text] [Related]
18. Glucocerebrosidase inhibitors for the treatment of Gaucher disease.
Trapero A; Llebaria A
Future Med Chem; 2013 Apr; 5(5):573-90. PubMed ID: 23573974
[TBL] [Abstract][Full Text] [Related]
19. Treating patients with Gaucher disease and parkinsonism: misrepresentation in a title.
Goker-Alpan O; Sidransky E
Parkinsonism Relat Disord; 2008; 14(1):81-2; author reply 83. PubMed ID: 17350320
[No Abstract] [Full Text] [Related]
20. Treatment of Gaucher's disease with OGT 918.
Kranda M
Lancet; 2000 Aug; 356(9230):677. PubMed ID: 10968455
[No Abstract] [Full Text] [Related]
[Next] [New Search]